In vitro activity of BMY-28100, a new oral cephalosporin.
AUTOR(ES)
Eliopoulos, G M
RESUMO
The activity of BMY-28100, a new orally administered cephalosporin, was compared with those of cephalexin and cefaclor. BMY-28100 was the most active drug against Staphylococcus aureus (MIC for 90% of strains tested [MIC90], 1.0 microgram/ml), streptococci (MIC90S, less than or equal to 0.125 microgram/ml), and Klebsiella pneumoniae (MIC90, 2 micrograms/ml). The drug was active against Haemophilus influenzae and gonococci but not against other organisms generally resistant to cephem antibiotics.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174801Documentos Relacionados
- Phase I study of single-dose BMY-28100, a new oral cephalosporin.
- BMY 28100, a new oral cephalosporin.
- Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.
- Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.
- In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.
